Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Marketing Surveillance of Fycompa in Korean Patients
2021-006003-15Phase 4
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perampanel in epilepsy, focal-onset epileptic seizures and primary generalized tonic-clonic seizure (PGTCS), sponsored by Eisai Co., Ltd. Primary endpoint: Number of Subjects With Adverse Events.
02
Drugs
perampanel
03
Conditions
epilepsyfocal-onset epileptic seizuresprimary generalized tonic-clonic seizure (PGTCS)
Beyond the preview
Go deeper on 2021-006003-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006003-15.